Exact Sciences Corp. announced preliminary unaudited financial results for Q4 and FY 2024, with expected revenues of $713 million for Q4 (up 10%) and $2.76 billion for the full year (up 10%). Screening revenue grew 13%, driven by Cologuard® and related tests, while Precision Oncology revenue rose 4%. The company plans to launch three new cancer diagnostics in 2025: Cologuard Plus™, Oncodetect™, and Cancerguard™. These innovations aim to enhance cancer prevention, early detection, and personalized treatment.